J&J Not Likely To Hold Its Peace At Merck/Schering Altar
• By The Pink Sheet
Merck and Schering-Plough are talking up the future - the commercial, pipeline and cost savings advantages of a proposed $41.1 billion merger - like newlyweds who have already tied the knot, danced the first dance and cut the cake. But there's an uninvited guest at the affair, Johnson & Johnson, a third-party with bargaining power that could step in to thwart Merck and Schering's happily ever after
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.
The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.